Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ACURX PHARMACEUTICALS INC (ACXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.95-8.18%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ACXP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Effective capital raise via unregistered equity sales | The company raised capital through unregistered equity sales in April 2026. | Intact | failure to raise capital or dilution worsens | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making biotech case, not an established compounder. The thesis is on watch: recent performance trails its industry cohort, while the evidence snapshot gives low confidence and mixed marks for key management priorities.
The snapshot provides no valuation multiple or direct measure of market expectations, so whether ACXP looks cheap, fair, or expensive versus peers is unclear. It does show weak financial performance and a loss-making profile, but does not establish how much of those conditions the market already assumes.
Near term, fundamentals face elevated earnings risk, with a 64% estimated miss probability, and recent financial performance is weak. Management’s ibezapolstat program expansion and leadership compensation alignment are both rated mixed; an April private placement and a separate negative capital-allocation event add uncertainty. Over the multi-year view, the snapshot gives too little evidence to establish a reliable path to improved results.
The multi-year thesis hinges in part on whether ACXP can make progress with its ibezapolstat program while addressing mixed management and capital-allocation signals. Near term, a weakening jobs trend could add pressure to cyclical names, while continued earnings strength from VRTX, REGN, and MRNA could support the Healthcare sector backdrop; misses or lower guidance from those companies could weaken that tailwind.
Over the next 1 to 3 years, ACXP remains a high-risk, low-confidence thesis with weak financial evidence and unclear valuation expectations; sector strength is a possible support, not proof of company progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Analysts expect EPS losses to improve from -$2.39 in 2026 to -$2.13 in 2027. |
| Intact |
| EPS loss worsens beyond -$2.13 in FY27 |
Diluted EPS: $-0.53 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -$1.5 per share. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.53 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Expand ibezapolstat program into recurrent C. difficile infection | Acurx aims to expand its ibezapolstat program into recurrent C. | Improving | progress score falls below 40% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain leadership salary reductions | A supporting condition in ACURX PHARMACEUTICALS INC's published investment case. The stated target is salary reductions sustained. | Intact | salary reductions reversed | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.77 → $-1.50 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-25 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-26 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-27 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-28 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-29 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-30 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-07-31 | $-2.13 | $0 | 2 / 2 |
| 2026-08-01 | $-2.13 | $0 | 2 / 2 |
| 2026-08-02 | $-2.13 | $0 | 2 / 2 |
| 2026-08-03 | $-2.13 | $0 | 2 / 2 |
| 2026-08-04 | $-2.13 | $0 | 2 / 2 |
| 2026-08-05 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-06 | $-2.13 | $0 | 2 / 2 |
| 2026-08-07 | $-2.13 | $0 | 2 / 2 |
| 2026-08-08 | $-2.13 | $0 | 2 / 2 |
| 2026-08-09 | $-2.13 | $0 | 2 / 2 |
| 2026-08-10 | $-2.13 | $0 | 2 / 2 |
| 2026-08-11 | $-2.13 | $0 | 2 / 2 |
| 2026-08-12 | $-2.13 | $0 | 2 / 2 |
| 2026-08-13 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-14 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-15 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-16 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-17 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-18 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-19 | $-1.77 | $3,535,000 | 1 / 2 |
| 2026-08-20 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-21 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-22 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-23 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-24 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-25 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-26 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-27 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-28 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-29 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-30 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-08-31 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-01 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-02 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-03 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-04 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-05 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-06 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-07 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-08 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-09 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-10 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-11 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-12 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-13 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-14 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-15 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-16 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-17 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-18 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-19 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-20 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-21 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-22 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-23 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-24 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-25 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-26 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-27 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-28 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-29 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-09-30 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-01 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-02 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-03 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-04 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-05 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-06 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-07 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-08 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-09 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-10 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-11 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-12 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-13 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-14 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-15 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-16 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-17 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-18 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-19 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-20 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-21 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-22 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-23 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-24 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-25 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-26 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-27 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-28 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-29 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-30 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-10-31 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-11-01 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-11-02 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-11-03 | $-1.50 | $3,535,000 | 1 / 3 |
| 2026-11-04 | $-1.50 | $3,535,000 | 1 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.